Prospective analysis of clinical and cytogenetic features of 435 cases of MDS diagnosed using the WHO (2001) classification: a prognostic scoring system for predicting survival in RCMD.
We characterized the prevalence, clinical and cytogenetic characteristics and survival of 435 patients diagnosed with de novo MDS in a single laboratory according to WHO criteria, and compared the utility of different scoring systems to predict survival for individual subtypes of MDS. The mean follow-up period was 25.1 (5.5-53.2) months. Our results confirm major differences in the age-distribution and prevalence of individual subtypes of MDS between Asian and Western patients with a median age of 58 years and a predominance of RCMD (69.9%). Survival rates were similar to those reported in the West: the 3-year survival rate for MDS was 46.7% with a median survival time for RCMD of 38 months and RAEB, 10 months. We found that the IPSS and WPSS scoring systems, which are weighted heavily by blast cell count and karyotype, were not independent predictors for survival in RCMD patients. Multivariate analysis demonstrated that a scoring system based on age (> or =60 years), ANC (<1.0 x 10(9)/L), Hb (<90 g/L), number of cytopenias and complex karyotype is a more useful predictor of survival in RCMD.
Wang
Xiao Qin
XQ
Fudan-Cinpathogen Clinical and Molecular Research Center (CMRC), Institute of Biomedical Sciences, Fudan University, Shanghai, China.|Huashan Hospital, Fudan University, Shanghai, China.
Ryder
John
J
Department of Pathology, School of Medicine, University of Colorado Denver, Colorado, USA.
Gross
Sherilyn A
SA
Fudan-Cinpathogen Clinical and Molecular Research Center (CMRC), Institute of Biomedical Sciences, Fudan University, Shanghai, China.|Department of Pharmaceutical Sciences, School of Pharmacy, University of Colorado Denver, Colorado, USA.
Lin
Guowei
G
Huashan Hospital, Fudan University, Shanghai, China.
Irons
Richard D
RD
Fudan-Cinpathogen Clinical and Molecular Research Center (CMRC), Institute of Biomedical Sciences, Fudan University, Shanghai, China. richard.irons@cinpathogen.com.|Huashan Hospital, Fudan University, Shanghai, China. richard.irons@cinpathogen.com.|Department of Pharmaceutical Sciences, School of Pharmacy, University of Colorado Denver, Colorado, USA. richard.irons@cinpathogen.com.|Department of Pathology, Fudan University, Shanghai, China. richard.irons@cinpathogen.com.|Cinpathogen, Inc, Boulder, USA. richard.irons@cinpathogen.com.|Cinpathogen, Inc, Shanghai, China. richard.irons@cinpathogen.com.|Central Laboratory, Fudan-Cinpathogen Clinical and Molecular Research Center, 1st Floor, No. 5 Building, 399 Cai Lun Road, Zhanjiang, Shanghai, 201210, China. richard.irons@cinpathogen.com.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D044466:Asian People / Q000706:statistics & numerical data*; D002681:China / Q000453:epidemiology; D002869:Chromosome Aberrations / Q000706:statistics & numerical data*; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009190:Myelodysplastic Syndromes / Q000145:classification / Q000175:diagnosis / Q000401:mortality; D011237:Predictive Value of Tests; D015995:Prevalence; D011379:Prognosis; D012307:Risk Factors; D014944:World Health Organization; D055815:Young Adult